Cellectar BioSciences Q3 net loss widens 79% to $7.97 million
- Cellectar BioSciences’ third-quarter 2026 net loss widened 79% year over year to $7.97 million.
- Research and development expenses more than doubled year over year to $5.44 million, primarily due to increased clinical trial activity.
- Cash totaled $24.58 million at September 30, 2026, with budgeted operations funded into the second quarter of 2027.
- First patients in the confirmatory Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia remain scheduled for dosing in early 2027.
- An FDA application seeking accelerated approval remains planned for the first half of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100715PRIMZONEFULLFEED9874097) on November 10, 2026, and is solely responsible for the information contained therein.